6. パーキンソン病 [臨床試験数:2,123,薬物数:2,046(DrugBank:324),標的遺伝子数:183,標的パスウェイ数:198

Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01892176June 201230/6/2013Effects of High-dose Coenzyme Q10 on Biomarkers of Oxidative Damage and Clinical Outcome in Parkinson DiseaseEffects of High-dose Coenzyme Q10 on Biomarkers of Oxidative Damage and Clinical Outcome in Parkinson DiseaseParkinson DiseaseDietary Supplement: coenzyme q10National University Hospital, SingaporeNULLCompleted21 MonthsN/ABoth20Phase 2/Phase 3Singapore
2NCT00740714December 200822/8/2008Effects of Coenzyme Q10 (CoQ) in Parkinson DiseaseEffects of Coenzyme Q10 in Parkinson Disease - Phase IIIParkinson DiseaseDrug: Coenzyme Q10 with vitamin E;Drug: placebo with vitamin EWeill Medical College of Cornell UniversityNational Institute of Neurological Disorders and Stroke (NINDS);University of RochesterTerminated30 YearsN/AAll600Phase 3United States;Canada
3NCT00180037September 20039/9/2005Coenzyme Q10 as a Symptomatic Treatment in Parkinson's DiseaseMulticenter, Placebo Controlled, Randomized, Double-Blinded Study: Coenzyme Q10 Nanodispersion Versus Placebo as Symptomatic Treatment in Parkinson's DiseaseParkinson's DiseaseDrug: Coenzyme Q10 Nanodispersion (Nanoquinone);Drug: PlaceboTechnische Universität DresdenDeutsche Parkinson-Vereinigung e.V.;MSE Pharmazeutika GmbH, Bad HomburgCompleted40 Years75 YearsBoth132Phase 3Germany
4NCT00004731September 199825/2/2000Parkinson's Disease Treatment With Coenzyme Q10Effects of Coenzyme Q10 in Early Parkinson's DiseaseParkinson's DiseaseDrug: Coenzyme Q10National Institute of Neurological Disorders and Stroke (NINDS)NULLCompleted30 YearsN/ABothPhase 2United States